RxSight, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Product sales | $24,546 | $30,340 | $82,680 | $101,871 |
| License and collaboration revenue | 40 | — | 6,540 | — |
| Total revenue | 24,586 | 30,340 | 89,220 | 101,871 |
| Costs and expenses: | ||||
| Cost of sales | 6,487 | 6,113 | 21,738 | 24,125 |
| Selling, general and administrative | 27,404 | 27,345 | 89,678 | 84,956 |
| Research and development | 9,213 | 9,060 | 27,922 | 29,644 |
| Total costs and expenses | 43,104 | 42,518 | 139,338 | 138,725 |
| Loss from operations | (18,518) | (12,178) | (50,118) | (36,854) |
| Other income (expense), net: | ||||
| Interest expense | (3) | (4) | (9) | (14) |
| Interest and other income | 2,325 | 2,376 | 6,043 | 7,137 |
| Loss before income taxes | (16,196) | (9,806) | (44,084) | (29,731) |
| Income tax expense | 28 | 10 | 122 | 61 |
| Net loss | $(16,224) | $(9,816) | $(44,206) | $(29,792) |
| Other comprehensive (loss) gain: | ||||
| Unrealized (loss) gain on short-term investments | (59) | 178 | (184) | (123) |
| Foreign currency translation gain (loss) | 18 | (1) | 31 | 18 |
| Total other comprehensive (loss) gain | (41) | 177 | (153) | (105) |
| Comprehensive loss | $(16,265) | $(9,639) | $(44,359) | $(29,897) |
| Net loss per share: | ||||
| Basic & diluted | $(0.39) | $(0.24) | $(1.07) | $(0.73) |
| Weighted-average shares used in computing net loss per share: | ||||
| Attributable to common stock, basic & diluted | 41,705,436 | 40,965,219 | 41,502,275 | 40,741,219 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.